Health News

  • Today December 15
Dec 13, 2019 13:47 KST
OncoSec CEO Sends Letter to Fellow Shareholders
Daniel O’Connor, President, Director & CEO of OncoSec Medical Incorporated (NASDAQ:ONCS) (the “Company” or “OncoSec”), a company developing late-stage intratumoral cancer immunotherapies, today sent t
Dec 12, 2019 15:51 KST
Seattle Genetics and Takeda Announce Additional Analyses of ADCETRIS® (Brentuximab Vedotin) ECHELON-1 and ECHELON-2 Phase 3 Clinical Trials at the 2019 ASH Annual Meeting
Seattle Genetics, Inc. (Nasdaq:SGEN) and Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) today announced additional analyses of results from the ECHELON-1 and ECHELON-2 frontline phase 3 tri
Dec 11, 2019 17:03 KST
Final results from the NuProtect study demonstrating efficacy of Nuwiq® (simoctocog alfa) in previously untreated patients (PUPs) presented at ASH 2019
Octapharma has announced today that the final results from the NuProtect study, the largest prospective study of a single factor VIII (FVIII) product in true PUPs with severe haemophilia A, were prese
Dec 11, 2019 16:13 KST
Solasia Announces License and Capital Alliance for SP-04 (PledOx®) with Maruho
Solasia Pharma K.K. (TSE: 4597, Headquarters: Tokyo, Japan, President & CEO: Yoshihiro Arai, hereinafter “Solasia”) announced today that it has entered into an exclusive license agreement with Maruho
Dec 10, 2019 23:50 KST
Panda Biotech Plans the Largest Industrial Hemp Processing Facility for Fiber and Cellulose in the United States
Dallas-based Panda Biotech today announced it is developing its first industrial hemp processing facility to produce high-quality, textile-grade fiber and premium cellulose. The “Panda High Plains Hem
Dec 10, 2019 17:13 KST
PanTheryx Bovine Colostrum Recognized as GRAS
PanTheryx, a biotechnology company committed to realizing the potential of bovine colostrum-based therapies to address a wide range of health conditions, today announced that an independent expert pan
Dec 10, 2019 17:04 KST
Takeda Demonstrates Its Long-Standing Commitment to Advancing Treatments for Rare Bleeding Disorders with Studies Highlighting Real-World Evidence and Investigational Gene Therapy at ASH 2019
Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE:TAK) (“Takeda”), today presented nine hematology poster presentations at the 61st American Society of Hematology (ASH) Annual Meeting that undersc
Dec 10, 2019 11:45 KST
OncoSec Releases Video Highlighting Why CGP/Sirtex Strategic Transaction Will Create Significant Shareholder Value
OncoSec Medical Incorporated (NASDAQ: ONCS) (the “Company” or “OncoSec”), a company developing late-stage intratumoral cancer immunotherapies, released a video featuring its President and Chief Execut
Dec 09, 2019 17:47 KST
Galderma Investigational Therapy Nemolizumab Granted FDA Breakthrough Therapy Designation for the Treatment of Patients Suffering from Prurigo Nodularis
Galderma today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to the investigational therapy nemolizumab for the treatment of pruritus associat
Dec 09, 2019 14:31 KST
Takeda to Present Results from the Phase 3 TOURMALINE-AL1 Trial of NINLARO in Patients with Amyloidosis
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) today announced that results of the TOURMALINE-AL1 trial will be presented during an oral session at the 61st American Society of Hematology (
Dec 06, 2019 11:06 KST
OncoSec Comments on Disturbing Elements of Alpha Holdings’ Revised Preliminary Proxy Filing
OncoSec Medical Incorporated (NASDAQ: ONCS) (the “Company” or “OncoSec”), a company developing late-stage intratumoral cancer immunotherapies, issued a statement highlighting a troubling voting scheme
Dec 05, 2019 12:22 KST
Macrogen Research Outcome from ‘GenomeAsia 100K’ Covered in Nature
The precision medicine and biotechnology company Macrogen (Chairman Jung-Sun Seo, www.macrogen.com) (KOSDAQ: 038290) announced on Dec 5 that the result of its Asian genome analysis, which has been per
Dec 03, 2019 11:13 KST
Octapharma announces the presentation of the final results from the NuProtect study of Nuwiq® (simoctocog alfa) in previously untreated patients (PUPs) at ASH 2019
Octapharma has announced that the final results of the NuProtect study will be presented by Dr Ri Liesner (Great Ormond Street Hospital for Children, London, UK) as an oral presentation at the 61st An
Dec 03, 2019 10:24 KST
OncoSec Sets the Record Straight on Alpha Holdings’ False and Misleading Statements
OncoSec Medical Incorporated (NASDAQ: ONCS), (the “Company” or “OncoSec”) a company developing late-stage intratumoral cancer immunotherapies, today issued the following letter to shareholders. The fu
Nov 27, 2019 11:14 KST
GN CORPORATION: Vision Restored with Corneal Cell Transplant Using a Nano Sheet Technique; Japanese Firm Granted Patent in India
A novel cell transplantation method to treat corneal endothelial diseases such as bullous keratopathy using a nano-composite gel sheet developed by Japanese scientists was granted Indian patent to GN
Nov 26, 2019 17:08 KST
Takeda Presents 18-Month Data from Pivotal Phase 3 Trial of Dengue Vaccine Candidate at the American Society of Tropical Medicine and Hygiene (ASTMH) 68th Annual Meeting
Takeda Pharmaceutical Company Limited (TSE:4502 / NYSE:TAK) (“Takeda”) today announced that updated results from the ongoing pivotal Phase 3 Tetravalent Immunization against Dengue Efficacy Study (TID
Nov 26, 2019 11:48 KST
Takeda Presents Long-Term Data in ALK+ NSCLC Showing ALUNBRIG® (brigatinib) Continues to Demonstrate Superiority in the First-Line After Two Years of Follow-Up
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) today announced updated data from the Phase 3 ALTA-1L trial, which evaluated ALUNBRIG versus crizotinib in adults with advanced anaplastic lym
Nov 26, 2019 10:09 KST
Zymeworks Highlights Advancing Clinical Collaboration with BeiGene and Updated ZW25 Phase 1 Data in HER2-Expressing Cancers at ESMO Asia Congress
Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional therapeutics, today announced updated Phase 1 data for single agent ZW25 in heavily pretreated patien
Nov 26, 2019 09:11 KST
Ferring and Blackstone Life Sciences Invest Over $570 Million USD in Novel Gene Therapy for Bladder Cancer Patients
Ferring Pharmaceuticals and Blackstone Life Sciences today announced the joint investment of over $570 million USD in nadofaragene firadenovec (rAd-IFN/Syn3), an investigational novel gene therapy in
Nov 25, 2019 13:44 KST
Study Uses Masimo Patient SafetyNet™ and rainbow Acoustic Monitoring® to Investigate the Incidence of Desaturation and Bradypnea in Postoperative Patients
Masimo (NASDAQ: MASI) announced today that in a study recently published in the Journal of Clinical Monitoring and Computing, researchers at Nippon Medical School in Tokyo, Japan used Masimo Patient S
Nov 22, 2019 11:21 KST
PanTheryx Announces Exclusive Multimillion Dollar Agreement between APS BioGroup and VitaDairy in Pediatric and Maternal Immunonutrition
PanTheryx, a biotechnology company committed to realizing the potential of bovine colostrum-based therapies, today announced a multimillion dollar agreement between its wholly-owned subsidiary APS Bio
Nov 18, 2019 14:00 KST
QIAGEN Receives Several Conditional, Non-binding Indications of Interest, and Decides to Enter Into Discussions to Explore Potential Strategic Alternatives
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) (“QIAGEN” or the “Company”) announces it has begun a review of potential strategic alternatives after receiving several conditional, non-binding
Nov 18, 2019 10:41 KST
Interim analysis from EMPRISE real-world study shows empagliflozin decreased risk of hospitalisation for heart failure compared with DPP-4 inhibitors and GLP-1 receptor agonists
A new interim analysis of three-year data from the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) real-world study on effectiveness shows that empagliflozin was associated with a decreas
Nov 15, 2019 11:37 KST
Takeda Announces 12 New Molecular Entities with the Potential for 14 Launches in the Next Five Years at 2019 R&D Day
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) will host an R&D meeting today beginning at 12:30 p.m. EST in New York City to outline how its science-first, patient-centric strat
Nov 14, 2019 06:00 KST
College of American Pathologists and Seoul National University Host Advanced Education for Doctors and Laboratory Scientists
In an effort to foster laboratory quality and further advance the evolving field of clinical microbiology, the College of American Pathologists (CAP), in partnership with Seoul National University Col
Nov 13, 2019 10:38 KST
Cook Medical’s Leadership Updates in Asia-pacific Reinforce Focus on Growth and Physician Relationships
Cook Medical announced today that Jean-Marc Creissel has been named vice president and director of Asia-Pacific. In his new role, Creissel will lead the Asia-Pacific teams to transform Cook Medical
Nov 13, 2019 10:00 KST
Boehringer Ingelheim and Lilly initiate first ever study to assess empagliflozin in people hospitalised for acute heart failure who have been stabilised
Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) today announced the initiation of EMPULSE, the sixth Phase III study in the empagliflozin heart failure programme. The study will assess whet
Nov 12, 2019 17:56 KST
NEC and VAXIMM Announce Collaboration to Advance Personalized Neoantigen Cancer Vaccines
NEC Corporation (NEC; TOKYO: 6701), a leader in IT and network technologies, and VAXIMM AG, a Swiss/German biotech company focused on developing oral T-cell immunotherapies, today announced that the c
Nov 12, 2019 10:45 KST
Takeda to Highlight Expanded Portfolio of Products Across Oncology and Hematology at 61st American Society of Hematology (ASH) Annual Meeting
Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE:TAK) today announced that it will present a total of 29 company-sponsored abstracts at the 61st American Society of Hematology (ASH) Annual Meetin
Nov 11, 2019 11:09 KST
South Korean Company, Yuhan Pharmaceuticals Partners with Cyclica to Advance R&D Across Two Separate Programs for Oncology
Renowned South Korean healthcare company, Yuhan Pharmaceuticals (Yuhan) and Cyclica Inc. (Cyclica), a leading neo biotechnology company announce a collaboration to apply Cyclica’s proprietary AI-integ
Nov 11, 2019 09:55 KST
New Analyses from the Phase 3 HELP Study™ Open-Label Extension in Hereditary Angioedema Evaluate Efficacy and Safety of TAKHZYRO® (lanadelumab-flyo) Injection During Extended Study Treatment Period
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced new data that further investigates the long-term safety and efficacy of TAKHZYRO® (lanadelumab-flyo) injection in p
Nov 08, 2019 16:35 KST
Phase 3 Trial of NINLARO™ (ixazomib) as First Line Maintenance Therapy Met Primary Endpoint in Multiple Myeloma Patients not treated with Stem Cell Transplantation
Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE: TAK) (“Takeda”) today announced the randomized, Phase 3 TOURMALINE-MM4 study met its primary endpoint of progression free survival (PFS). The tri
Nov 08, 2019 14:38 KST
FIND Collaborates with SpeeDx and QuantuMDx
SpeeDx Pty. Ltd. and QuantuMDx Group Ltd. today announced a collaboration with the Foundation for Innovative New Diagnostics (FIND). The global non-profit organization drives development and delivery
Nov 07, 2019 19:36 KST
Promega Enters Global Collaboration with Merck to Develop Microsatellite Instability (MSI) Companion Diagnostic for Use with KEYTRUDA®
Promega Corporation today announced it has entered into a global collaboration with Merck, known as MSD outside the United States and Canada, to develop Promega’s microsatellite instability (MSI) tech
Nov 07, 2019 18:41 KST
Takeda’s Dengue Vaccine Candidate Demonstrates Protection in Children Ages Four to 16 Years, Regardless of Previous Dengue Exposure
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that results from the primary endpoint analysis of the ongoing pivotal Phase 3 Tetravalent Immunization against Den
Nov 07, 2019 16:14 KST
Takeda Unveils New Dengue Vaccine Manufacturing Plant in Germany
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced the opening of its new manufacturing plant in Singen, Germany, for its dengue vaccine candidate, TAK-003. The Singe
Nov 07, 2019 15:48 KST
Samsung Bioepis Enters into Commercialization Agreement for Next-Generation Biosimilar Candidates
Samsung Bioepis Co., Ltd. announced today that it has entered into a new commercialization agreement with Biogen (Nasdaq: BIIB) for two biosimilar candidates under development by Samsung Bioepis, SB11
Nov 06, 2019 18:02 KST
Octapharma’s fibryga® Receives European Label Extension to Treat Acquired Fibrinogen Deficiency (AFD)
Octapharma announced today that the human fibrinogen concentrate fibryga® has received approval for use in treatment of acquired fibrinogen deficiency (AFD) in 15 European countries. The approval exte
Nov 06, 2019 16:01 KST
Takeda and MD Anderson Announce Collaboration to Accelerate the Development of Clinical-Stage, Off-The-Shelf CAR NK-Cell Therapy Platform
The University of Texas MD Anderson Cancer Center and Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced an exclusive license agreement and research agreement to deve
Nov 05, 2019 16:14 KST
Takeda Continues Strategic Divestitures With Sale of Select OTC and Non-Core Assets to STADA for $660 Million USD
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that it has entered into an agreement to divest a portfolio of select products to STADA Arzneimittel AG (“STADA”),
Nov 04, 2019 16:23 KST
Takeda Reports Solid Second Quarter FY2019 Results and Raises Profit Guidance for the Full Year
Takeda Pharmaceutical Company Limited (TOKYO:4502)(NYSE:TAK): This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191030006224/en/ Underl
Nov 01, 2019 18:06 KST
The Mary Kay Foundation Awards $3.1 Million in Cancer Research and Domestic Violence Shelter Grants
The Mary Kay FoundationSM recently awarded over $3 million in cancer research and domestic violence shelter grants around the country. The Mary Kay Foundation was established in 1996 with the overarch
Nov 01, 2019 17:38 KST
Octapharma announces publication of data on fibryga® for the treatment of acquired fibrinogen deficiency in patients undergoing cardiac surgery
Octapharma has announced the publication of new data demonstrating that the fibrinogen concentrate fibryga® is an effective alternative to cryoprecipitate for patients with severe bleeding during card
Nov 01, 2019 14:57 KST
Promethera Biosciences: Announcement Regarding Business Activities in Japan
Promethera Biosciences SA (Group), a global innovator in cell-based medicines and liver diseases, announced the foundation of a new branch office in Tokyo, Promethera Biosciences Japan Branch Ltd on M
Nov 01, 2019 13:02 KST
Masimo Announces CE Marking of Radius Capnography™ for the Root® Patient Monitoring and Connectivity Platform
Masimo (NASDAQ: MASI) announced today that Radius Capnography™, a portable real-time capnograph with wireless Bluetooth® connectivity, has received CE marking. Radius Capnography connects with the Roo
Oct 31, 2019 16:29 KST
The Mary Kay Foundation Donates $100,000 to Baylor Scott & White to Support Triple Negative Breast Cancer Research
The Mary Kay Foundation℠, a decades-long leader in the mission to eliminate cancers affecting women, recently donated $100,000 to Baylor Scott & White Dallas Foundation to help fund research conducted
Oct 30, 2019 13:41 KST
Terns Pharmaceuticals Receives Fast Track Designation From the FDA for TERN-101, an FXR Agonist for the Treatment of NASH
Terns Pharmaceuticals, Inc., a global biopharmaceutical company focused on discovering and developing innovative therapies to treat non-alcoholic steatohepatitis (NASH) and cancer, today announced tha
Oct 30, 2019 10:26 KST
Boehringer Ingelheim Advances First Pan-KRAS Inhibitor BI 1701963 into Clinical Testing
Boehringer Ingelheim today presented promising preclinical data from its pan-KRAS program including the novel, oral inhibitor BI 1701963 at the AACR-NCI-EORTC International Conference on Molecular Tar
Oct 28, 2019 11:33 KST
A Decade of Innovation and Growth: Cook Korea 10th Anniversary
Cook Medical celebrated its 10-year anniversary with a special event that marked a major milestone - a decade of successful customer service, innovation and employee development. Back in 2000, Cook
Oct 25, 2019 08:00 KST
Global Health Progress Launched to Drive Cross-sectoral Collaborations in Support of the Sustainable Development Goals (SDGs)
To support the SDGs, with a particular focus on SDG 17: Partnership for The Goals, the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) has launched Global Health Progre
Oct 23, 2019 19:10 KST
Covetrus Announces CEO and Chairman Transition
Covetrus (NASDAQ: CVET), a global leader in animal-health technology and services, today announced that Benjamin Shaw has stepped down as the company’s president and chief executive officer and will t
Oct 23, 2019 17:01 KST
Takeda Acquires License for First-In-Class Celiac Disease Therapy from COUR Pharmaceuticals Following Positive Phase 2a Proof-of-Concept Study
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) and COUR Pharmaceutical Development Company, Inc. (“COUR”) today announced that Takeda has acquired an exclusive global license to
Oct 23, 2019 11:06 KST
Solasia Announces Approval of episil® oral liquid in South Korea
Solasia Pharma K.K. (TSE: 4597, Headquarters: Tokyo, Japan, President & CEO: Yoshihiro Arai, hereinafter “Solasia”), a specialty pharmaceutical company based in Asia, today officially announced that e
Oct 22, 2019 11:13 KST
ResMed Introduces AirFit N30, World’s First Tube-Down Nasal Cradle CPAP Mask
ResMed (NYSE: RMD) (ASX: RMD) today introduced AirFit N30, the world’s first tube-down nasal cradle CPAP mask with a front-facing tube - a brand-new option for sleep apnea treatment. ResMed’s light
Oct 21, 2019 16:43 KST
Retrospective Real-World Comparative Analysis Highlights Safety of Vedolizumab and Anti-TNFα Therapies in Biologic-Naïve Patients with Ulcerative Colitis or Crohn’s Disease
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced results from a retrospective chart review study (EVOLVE), which investigated the likelihood of serious adverse even
Oct 21, 2019 13:18 KST
New Research Reveals Updated Patient Preferences on Digital Health Technology
ResMed (NYSE: RMD, ASX: RMD) today announced results from a company-led survey, revealing new patient preferences on digital health technology. The survey highlights a reason for optimism that the mar
Oct 21, 2019 10:35 KST
Concept Medical is Granted CE Certification for Their Sirolimus Coated MagicTouch Group of Products
The CE certified products/brands are as listed below: 1. MagicTouch - PTA (Sirolimus Coated PTA Balloon Catheter) for peripheral arterial disease 2. MagicTouch - ED (Sirolimus Coated Balloon Cathe
Oct 18, 2019 13:10 KST
Sonion Joins Global Qualcomm Extension Program
Sonion®, global leader in designing and manufacturing components and solutions for hearing aids, in-ear earphones and hearables/wearables, today announced that it is now a member of the Qualcomm® Exte
Oct 17, 2019 14:20 KST
Johns Hopkins Center for Health Security, World Economic Forum and Bill & Melinda Gates Foundation Host Pandemic Exercise and Livestream
The Johns Hopkins Center for Health Security, with the World Economic Forum and the Bill & Melinda Gates Foundation, will host Event 201, a multimedia global pandemic exercise on Friday, Oct. 18, 2019
Oct 17, 2019 11:25 KST
Accomplishments of Dr. Steven Rosenberg in Cancer Immunotherapy Inspire Young Researchers in Japan & XIV Fujio Cup Quiz on Stem Cells Is Won by India.
Utilizing the capability of one’s own immune system to tackle cancer, an out-of-the box idea was the brain child of Dr. Steven Rosenberg almost three decades ago. His initiative which paved way for a
Oct 17, 2019 10:45 KST
Boehringer Ingelheim Announces First Patient Enrolled in Phase II Trial of Novel Cystic Fibrosis Treatment (BALANCE-CF™ 1)
Boehringer Ingelheim today announced the first patient enrolled in its Phase II clinical trial BALANCE-CF™ 1 to evaluate a new potential treatment for cystic fibrosis.[1,2] The trial will investigate
Oct 16, 2019 13:33 KST
Terns Pharmaceuticals to Present Positive Preclinical Data on FXR Agonist TERN-101 at The Liver Meeting® 2019
Terns Pharmaceuticals, Inc., a global biopharmaceutical company focused on discovering and developing innovative therapies to treat non-alcoholic steatohepatitis (NASH) and cancer, today announced it
Oct 15, 2019 16:23 KST
Takeda Agrees to Divest Select OTC and Non-core Assets to Acino for Over $200 Million USD
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that it has entered into an agreement to divest a portfolio of select over-the-counter (OTC) and prescription pharm
Oct 15, 2019 09:29 KST
Analysis of Patients With Prior Gastrectomy Treated With LONSURF® (trifluridine/tipiracil) Published in JAMA Oncology
Servier and its partner Taiho Oncology, Inc. (US), a subsidiary of Taiho Pharmaceutical Co., Ltd. (Japan), announced today that detailed results from the analysis of patients with prior gastrectomy en
Oct 11, 2019 11:41 KST
Perspectum announces partnership with Precious Medical Centre
Perspectum, the leading provider of diagnostic solutions for metabolic disease and cancer, is partnering Precious Medical, a premier imaging centre in Singapore, following a successful launch event th
Oct 10, 2019 17:26 KST
Galderma Advances Phase 3 Clinical Study with Nemolizumab in Moderate-to-Severe Atopic Dermatitis
Galderma, a global leader focused on meeting the world's increasing skin health needs, announced that it has enrolled the first patients in a new Phase 3 clinical study with nemolizumab, an investigat
Oct 10, 2019 16:44 KST
National Institute for Health and Clinical Excellence Maintains Previous Recommendation for EXOGEN® Ultrasound Bone Healing System
Bioventus, a global leader in orthobiologic solutions, has received notice from the United Kingdom’s National Institute for Health and Clinical Excellence (NICE) that it has updated its guidance (MTG1
ABB's mobile and autonomous YuMi® laboratory robot concept will be designed to work alongside medic
Oct 10, 2019 11:02 KST
ABB Demonstrates Concept of Mobile Laboratory Robot for Hospital of the Future
ABB today opened its first global healthcare research hub on the Texas Medical Center (TMC) campus, in Houston, Texas - showcasing a number of concept technologies, including a mobile YuMi® robot, whi
Oct 10, 2019 10:48 KST
Samsung Bioepis Presents Real-world Data of BENEPALI™ (etanercept) in Patients with Psoriasis at European Academy of Dermatology and Venereology (EADV) Congress
Samsung Bioepis Co., Ltd. today announced real-world data of BENEPALI™ in patients with moderate to severe psoriasis from the British Association of Dermatologists Biologics and Immunomodulators Regis
Oct 04, 2019 19:25 KST
MPEG LA Announces Peer Reviewed Article Featured in Nucleic Acid Therapeutics
World technology licensing leader MPEG LA today announced publication of a peer reviewed article in the October 2019 issue of Nucleic Acid Therapeutics on MPEG LA’s proprietary Increscent Therapeutics
Oct 01, 2019 16:37 KST
New data reinforces benefits of Spiolto® Respimat® in improving patient outcomes
Boehringer Ingelheim announced Spiolto® (tiotropium/olodaterol) Respimat® data being presented at the European Respiratory Society (ERS) 2019 Congress. The results show the benefits of tiotropium/olod
Oct 01, 2019 16:29 KST
Servier acquires non-Hodgkin B-cell lymphoma treatment PIXUVRI® (pixantrone) from CTI BioPharma, strengthening the Servier oncology portfolio
Servier, an independent international pharmaceutical company, today announced the acquisition of PIXUVRI® from CTI BioPharma. PIXUVRI is a treatment for adult patients with multiply relapsed or refrac
Oct 01, 2019 12:05 KST
Update of Summary of Product Characteristics for Nuwiq® includes data on effective bleed protection with twice-weekly dosing with personalised prophylaxis
Octapharma announced today that the European Medicines Agency has authorised an updated Summary of Product Characteristics (SmPC) for Nuwiq® that includes information on personalised prophylaxis in pa
Sep 30, 2019 15:43 KST
INBUILD® meets primary endpoint - study evaluated nintedanib in patients across a range of progressive fibrosing interstitial lung diseases[1]
Boehringer Ingelheim announced today that in the Phase III INBUILD® trial nintedanib slowed lung function decline by 57% across the overall study population, as assessed by the annual rate of decline
Sep 27, 2019 11:13 KST
Samsung Bioepis Announces Phase 3 Results of SB8, Bevacizumab Biosimilar Candidate, at the European Society for Medical Oncology (ESMO) 2019 Congress
Samsung Bioepis Co., Ltd. today announced results from the Phase 3 study evaluating the efficacy and safety of SB8, a bevacizumab biosimilar candidate, compared to reference bevacizumab in patients wi
25 per page50 per page75 per page100 per page